147 related articles for article (PubMed ID: 19733606)
1. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Luo YL; Zhang MY; Wu WY; Li CB; Lu Z; Li QW
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1522-5. PubMed ID: 19733606
[TBL] [Abstract][Full Text] [Related]
2. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
Nemeroff CB; Thase ME;
J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
6. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
[TBL] [Abstract][Full Text] [Related]
7. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.
Honig A; Kuyper AM; Schene AH; van Melle JP; de Jonge P; Tulner DM; Schins A; Crijns HJ; Kuijpers PM; Vossen H; Lousberg R; Ormel J;
Psychosom Med; 2007; 69(7):606-13. PubMed ID: 17846258
[TBL] [Abstract][Full Text] [Related]
8. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
10. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial.
Volz HP; Murck H; Kasper S; Möller HJ
Psychopharmacology (Berl); 2002 Nov; 164(3):294-300. PubMed ID: 12424553
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
12. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
13. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
14. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
Cornelius JR; Salloum IM; Thase ME; Haskett RF; Daley DC; Jones-Barlock A; Upsher C; Perel JM
Psychopharmacol Bull; 1998; 34(1):117-21. PubMed ID: 9564208
[TBL] [Abstract][Full Text] [Related]
16. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial.
Müller T; Mannel M; Murck H; Rahlfs VW
Psychosom Med; 2004; 66(4):538-47. PubMed ID: 15272100
[TBL] [Abstract][Full Text] [Related]
17. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
Sayyah M; Boostani H; Pakseresht S; Malayeri A
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):362-5. PubMed ID: 20035818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
